241 related articles for article (PubMed ID: 29865280)
21. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
22. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
24. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
25. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.
Sieben M; Schäfer P; Dinsart C; Galle PR; Moehler M
Int J Cancer; 2013 Jun; 132(11):2548-56. PubMed ID: 23151948
[TBL] [Abstract][Full Text] [Related]
26. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
28. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
Bhat R; Rommelaere J
BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
Bhat R; Dempe S; Dinsart C; Rommelaere J
Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
[TBL] [Abstract][Full Text] [Related]
30. Using targeted virotherapy to treat a resistant Ewing sarcoma model: from the bedside to the bench and back.
Abdelbary H; Brown CW; Werier J; Bell J
ScientificWorldJournal; 2014; 2014():171439. PubMed ID: 24672293
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
[TBL] [Abstract][Full Text] [Related]
32. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
Akladios C; Aprahamian M
Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
[TBL] [Abstract][Full Text] [Related]
33. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.
Schober SJ; Thiede M; Gassmann H; von Ofen AJ; Knoch P; Eck J; Prexler C; Kordass-Wally C; Hauer J; Burdach S; Holm PS; Thiel U
Front Immunol; 2024; 15():1330868. PubMed ID: 38318175
[TBL] [Abstract][Full Text] [Related]
34. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
35. The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.
Schober SJ; Schoening C; Eck J; Middendorf C; Lutsch J; Knoch P; von Ofen AJ; Gassmann H; Thiede M; Hauer J; Kolk A; Mantwill K; Gschwend JE; Burdach SEG; Nawroth R; Thiel U; Holm PS
Clin Cancer Res; 2023 May; 29(10):1996-2011. PubMed ID: 36892582
[TBL] [Abstract][Full Text] [Related]
36. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
[TBL] [Abstract][Full Text] [Related]
37. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A
EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664
[TBL] [Abstract][Full Text] [Related]
38. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
Angelova AL; Aprahamian M; Grekova SP; Hajri A; Leuchs B; Giese NA; Dinsart C; Herrmann A; Balboni G; Rommelaere J; Raykov Z
Clin Cancer Res; 2009 Jan; 15(2):511-9. PubMed ID: 19147756
[TBL] [Abstract][Full Text] [Related]
39. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
40. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.
Hajda J; Lehmann M; Krebs O; Kieser M; Geletneky K; Jäger D; Dahm M; Huber B; Schöning T; Sedlaczek O; Stenzinger A; Halama N; Daniel V; Leuchs B; Angelova A; Rommelaere J; Engeland CE; Springfeld C; Ungerechts G
BMC Cancer; 2017 Aug; 17(1):576. PubMed ID: 28851316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
